NIH Guide: Weekly Index for April 15, 2022

Funding Opportunities

• AHRQ Administrative Supplements for Grants in Health Services Research
  (PA-22-168)
  Agency for Healthcare Research and Quality
  Application Receipt Date(s): June 26, October 26, February 26 by 5:00 PM local time of applicant organization. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.
• Imaging, Biomarkers and Digital Pathomics for the Early Detection of Premetastatic Cancer and Precancerous Lesions Associated with Lethal Phenotypes (R01 Clinical Trial Optional)
  (PAR-22-131)
  National Cancer Institute
  Application Receipt Date(s): Multiple dates, see announcement.
• Paul Calabresi Career Development Award for Clinical Oncology (K12 Clinical Trial Optional)
  (PAR-22-136)
  National Cancer Institute
  Application Receipt Date(s): New: June 15, 2022; June 15, 2023, June 17, 2024 Resubmission/Renewal: June 15, 2022; June 15, 2023, June 17, 2024 All applications are due by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on the listed date(s). Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.
• NEI Cooperative Agreement for Early-Stage Clinical Trials with Greater than Minimal Risk (U01 Clinical Trial Required)
  (PAR-22-149)
  National Eye Institute
  Application Receipt Date(s): May 7, 2025
• IDeA Clinical Research Resource Center (U24 Clinical Trial Not Allowed)
  (PAR-22-150)
  National Institute of General Medical Sciences
  Application Receipt Date(s): September 26, 2022
• Research Opportunities in Established Cancer Epidemiology Cohort Studies (U01 Clinical Trial Not Allowed)
  (PAR-22-162)
  National Cancer Institute
  Application Receipt Date(s): November 18, 2024
• Specialized Alcohol Research Centers (P50 Clinical trial Optional)
  (RFA-AA-22-001)
  National Institute on Alcohol Abuse and Alcoholism
  Application Receipt Date(s): November 15, 2022
• Comprehensive Alcohol Research Centers (P60 Clinical trial Optional)
  (RFA-AA-22-002)
  National Institute on Alcohol Abuse and Alcoholism
  Application Receipt Date(s): November 15, 2022
• Transition to Aging Research for Predoctoral Students (F99/K00 Clinical Trial Not Allowed)
  (RFA-AG-23-016)
  National Institute on Aging
  Application Receipt Date(s): October 18, 2024
• Limited Interaction Targeted Epidemiology: Viral Suppression (LITE-VS) (UG3/UH3 Clinical Trial Optional)
  (RFA-AI-22-024)
  National Institute of Allergy and Infectious Diseases
  National Institute on Drug Abuse
  National Institute of Mental Health
  Application Receipt Date(s): August 3, 2022
• Cystic Fibrosis Research and Translation Centers (P30 Clinical Trial Optional)
  (RFA-DK-22-011)
  National Institute of Diabetes and Digestive and Kidney Diseases
  Application Receipt Date(s): July 28, 2022
• Innovative Multi-Level Approaches and Strategies to Prevent, Test and Treat HIV in Primary Care Settings in Health Disparity Populations in Geographic Hot Spots in the United States (R01 - Clinical Trial Required)
  (RFA-MD-22-009)
  National Institute on Minority Health and Health Disparities
  Office of Research on Women's Health
  Application Receipt Date(s): August 15, 2022
• Technologies and Assays for Therapeutic Genome Editing INDs (U01, Clinical Trial Not Allowed)
  (RFA-RM-22-014)
  Office of Strategic Coordination (Common Fund)
  Application Receipt Date(s): July 19, 2022
• IND-enabling Studies of Somatic Genome Editing Therapeutic Leads (U19, Clinical Trial Not allowed)
  (RFA-RM-22-015)
  Office of Strategic Coordination (Common Fund)
  Application Receipt Date(s): July 19, 2022
• Platform Clinical Trials of Genome Editors in Multiple Diseases (UG3/UH3, Clinical Trial Required)
  (RFA-RM-22-016)
  Office of Strategic Coordination (Common Fund)
  Application Receipt Date(s): July 19, 2022
• Somatic Cell Genome Editing Program Translational Coordination and Dissemination Center (TCDC) (U24 - Clinical Trial Not Allowed)
  (RFA-RM-22-017)
  Office of Strategic Coordination (Common Fund)
  Application Receipt Date(s): July 19, 2022
• NIH Directors Pioneer Award Program (DP1 Clinical Trial Optional)
  (RFA-RM-22-018)
  Office of Strategic Coordination (Common Fund)
  Application Receipt Date(s): Multiple dates, see announcement.
• Pilot Projects Investigating Understudied G Protein-Coupled Receptors, Ion Channels, and Protein Kinases (R03 Clinical Trial Not Allowed)
  (RFA-RM-22-024)
  Office of Strategic Coordination (Common Fund)
  Application Receipt Date(s): July 15, 2022